Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24463148 | 0.85 | KDM4E (0.33) | KDM4EALDH1A1LMNA | |
| SCHEMBL26790700 | 0.82 | — | — | |
| SCHEMBL30391150 | 0.77 | KDM4E (0.33) | KDM4EALDH1A1LMNANPC1RAB9A | |
| SCHEMBL24463640 | 0.77 | KDM4E (0.33) | KDM4EALDH1A1LMNANPC1RAB9A | |
| SCHEMBL26790713 | 0.75 | MEN1 (0.36) | LMNANPC1POLBRAB9A | |
| SCHEMBL24463428 | 0.71 | CYP1A2 (0.35) | KDM4EALDH1A1LMNANPC1MAPT | |
| SCHEMBL26790782 | 0.69 | PTGES (0.36) | LMNANPC1RAB9A | |
| SCHEMBL26661686 | 0.68 | KDM4E (0.47) | KDM4EALDH1A1LMNANPC1POLB | |
| SCHEMBL31398959 | 0.68 | CYP1A2 (0.32) | — | |
| SCHEMBL24463425 | 0.67 | KDM4E (0.35) | KDM4ELMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | KDM4E 2742/4885ALDH1A1 2169/4885LMNA 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.